You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBosentan
Accession NumberDB00559  (APRD00829)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionBosentan is a dual endothelin receptor antagonist important in the treatment of pulmonary artery hypertension (PAH). It is licensed in the United States, the European Union and other countries by Actelion Pharmaceuticals for the management of PAH under the trade name Tracleer®. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure.
Structure
Thumb
Synonyms
4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl) benzenesulfornamide
bosentán
bosentan
bosentanum
p-tert-Butyl-N-(6-(2-hydroxyethoxy)-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulfonamide
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Accel-bosentanTablet125 mgOralAccel Pharma IncNot applicableNot applicableCanada
Act BosentanTablet125 mgOralActavis Pharma Company2012-06-05Not applicableCanada
Act BosentanTablet62.5 mgOralActavis Pharma Company2012-06-05Not applicableCanada
Bosentan TabletsTablet125 mgOralAccord Healthcare Inc2014-11-132015-06-02Canada
Ipg-bosentanTablet62.5 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-bosentanTablet125 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-bosentanTablet62.5 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-bosentanTablet125 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mylan-bosentanTablet62.5 mgOralMylan Pharmaceuticals Ulc2012-05-29Not applicableCanada
Mylan-bosentanTablet125.0 mgOralMylan Pharmaceuticals Ulc2012-05-29Not applicableCanada
PMS-bosentanTablet62.5 mgOralPharmascience Inc2012-06-12Not applicableCanada
PMS-bosentanTablet125 mgOralPharmascience Inc2012-06-12Not applicableCanada
Sandoz BosentanTablet62.5 mgOralSandoz Canada Incorporated2012-06-13Not applicableCanada
Sandoz BosentanTablet125 mgOralSandoz Canada Incorporated2012-06-13Not applicableCanada
StayveerTablet, film coated125 mgOralMarklas Nederlands Bv   2013-06-24Not applicableEu
StayveerTablet, film coated62.5 mgOralMarklas Nederlands Bv   2013-06-24Not applicableEu
StayveerTablet, film coated125 mgOralMarklas Nederlands Bv   2013-06-24Not applicableEu
StayveerTablet, film coated62.5 mgOralMarklas Nederlands Bv   2013-06-24Not applicableEu
Teva-bosentanTablet125.0 mgOralTeva Canada Limited2012-12-28Not applicableCanada
Teva-bosentanTablet62.5 mgOralTeva Canada Limited2012-12-12Not applicableCanada
TracleerTablet, film coated62.5 mgOralActelion Registration Ltd2002-05-15Not applicableEu
TracleerTablet62.5 mgOralActelion Pharmaceuticals Ltd2001-12-14Not applicableCanada
TracleerTablet, film coated125 mgOralActelion Registration Ltd2002-05-15Not applicableEu
TracleerTablet, film coated62.5 mgOralActelion Registration Ltd2002-05-15Not applicableEu
TracleerTablet125 mgOralActelion Pharmaceuticals Ltd2001-12-14Not applicableCanada
TracleerTablet, for suspension32 mgOralActelion Registration Ltd2002-05-15Not applicableEu
TracleerTablet, film coated62.5 mgOralActelion Registration Ltd2002-05-15Not applicableEu
TracleerTablet, film coated62.5 mg/1OralActelion Pharmaceuticals US, Inc.2001-11-20Not applicableUs
TracleerTablet, film coated125 mgOralActelion Registration Ltd2002-05-15Not applicableEu
TracleerTablet, film coated125 mg/1OralActelion Pharmaceuticals US, Inc.2001-11-20Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-bosentanTablet62.5 mgOralApotex IncNot applicableNot applicableCanada
Apo-bosentanTablet125.0 mgOralApotex IncNot applicableNot applicableCanada
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Bosentan monohydrate
157212-55-0
Thumb
  • InChI Key: SXTRWVVIEPWAKM-UHFFFAOYSA-N
  • Monoisotopic Mass: 569.194419532
  • Average Mass: 569.63
DBSALT001842
Categories
UNIIXUL93R30K2
CAS number147536-97-8
WeightAverage: 551.614
Monoisotopic: 551.183854375
Chemical FormulaC27H29N5O6S
InChI KeyGJPICJJJRGTNOD-UHFFFAOYSA-N
InChI
InChI=1S/C27H29N5O6S/c1-27(2,3)18-10-12-19(13-11-18)39(34,35)32-23-22(38-21-9-6-5-8-20(21)36-4)26(37-17-16-33)31-25(30-23)24-28-14-7-15-29-24/h5-15,33H,16-17H2,1-4H3,(H,30,31,32)
IUPAC Name
4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]benzene-1-sulfonamide
SMILES
COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)N=C(N=C1OCCO)C1=NC=CC=N1
Pharmacology
IndicationUsed in the treatment of pulmonary arterial hypertension (PAH), to improve exercise ability and to decrease the rate of clinical worsening (in patients with WHO Class III or IV symptoms).
Structured Indications
PharmacodynamicsBosentan belongs to a class of drugs known as endothelin receptor antagonists (ERAs). Patients with PAH have elevated levels of endothelin, a potent blood vessel constrictor, in their plasma and lung tissue. Bosentan blocks the binding of endothelin to its receptors, thereby negating endothelin's deleterious effects.
Mechanism of actionEndothelin-1 (ET-1) is a neurohormone, the effects of which are mediated by binding to ETA and ETB receptors in the endothelium and vascular smooth muscle. ET-1 concentrations are elevated in plasma and lung tissue of patients with pulmonary arterial hypertension, suggesting a pathogenic role for ET-1 in this disease. Bosentan is a specific and competitive antagonist at endothelin receptor types ETA and ETB. Bosentan has a slightly higher affinity for ETA receptors than for ETB receptors.
TargetKindPharmacological actionActionsOrganismUniProt ID
Endothelin B receptorProteinyes
antagonist
HumanP24530 details
Endothelin-1 receptorProteinyes
antagonist
HumanP25101 details
Related Articles
AbsorptionAbsolute bioavailability is approximately 50% and food does not affect absorption.
Volume of distribution
  • 18 L
Protein bindingGreater than 98% to plasma proteins, mainly albumin.
Metabolism

Bosentan is metabolized in the liver by the cytochrome P450 enzymes CYP2C9 and CYP3A4 (and possibly CYP2C19), producing three metabolites, one of which, Ro 48-5033, is pharmacologically active and may contribute 10 to 20% to the total activity of the parent compound.

SubstrateEnzymesProduct
Bosentan
Bosentan metabolite Ro 48-5033Details
Bosentan
Bosentan metabolite Ro 47-8634Details
Bosentan metabolite Ro 48-5033
Not Available
Bosentan metabolite Ro 64-1056Details
Bosentan metabolite Ro 47-8634
Not Available
Bosentan metabolite Ro 64-1056Details
Route of eliminationBosentan is eliminated by biliary excretion following metabolism in the liver.
Half lifeTerminal elimination half-life is about 5 hours in healthy adult subjects.
Clearance
  • 4 L/h [patients with pulmonary arterial hypertension]
ToxicityBosentan has been given as a single dose of up to 2400 mg in normal volunteers, or up to 2000 mg/day for 2 months in patients, without any major clinical consequences. The most common side effect was headache of mild to moderate intensity. In the cyclosporine A interaction study, in which doses of 500 and 1000 mg b.i.d. of bosentan were given concomitantly with cyclosporine A, trough plasma concentrations of bosentan increased 30-fold, resulting in severe headache, nausea, and vomiting, but no serious adverse events. Mild decreases in blood pressure and increases in heart rate were observed. There is no specific experience of overdosage with bosentan beyond the doses described above. Massive overdosage may result in pronounced hypotension requiring active cardiovascular support.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Bosentan.Experimental
AbirateroneThe serum concentration of Bosentan can be increased when it is combined with Abiraterone.Approved
AcebutololBosentan may increase the hypotensive activities of Acebutolol.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be increased when combined with Bosentan.Approved
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Bosentan.Approved
AdinazolamThe serum concentration of Adinazolam can be decreased when it is combined with Bosentan.Approved
AlbendazoleThe serum concentration of Albendazole can be decreased when it is combined with Bosentan.Approved, Vet Approved
AlclometasoneThe serum concentration of Alclometasone can be decreased when it is combined with Bosentan.Approved
AlfentanilThe serum concentration of Alfentanil can be decreased when it is combined with Bosentan.Approved, Illicit
AlfuzosinThe serum concentration of Alfuzosin can be decreased when it is combined with Bosentan.Approved, Investigational
AliskirenThe serum concentration of Aliskiren can be decreased when it is combined with Bosentan.Approved, Investigational
AllylestrenolThe serum concentration of Allylestrenol can be decreased when it is combined with Bosentan.Approved
AlmotriptanThe serum concentration of Almotriptan can be decreased when it is combined with Bosentan.Approved, Investigational
AlogliptinThe serum concentration of Alogliptin can be decreased when it is combined with Bosentan.Approved
AlosetronThe serum concentration of Alosetron can be decreased when it is combined with Bosentan.Approved, Withdrawn
AlprazolamThe serum concentration of Alprazolam can be decreased when it is combined with Bosentan.Approved, Illicit, Investigational
AlprenololBosentan may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Bosentan.Approved, Investigational
AmbroxolThe serum concentration of Ambroxol can be decreased when it is combined with Bosentan.Approved
AmifostineBosentan may increase the hypotensive activities of Amifostine.Approved, Investigational
AminophenazoneThe serum concentration of Aminophenazone can be decreased when it is combined with Bosentan.Approved, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Bosentan.Approved
AmiodaroneThe serum concentration of Bosentan can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Bosentan.Approved
AmlodipineThe serum concentration of Amlodipine can be decreased when it is combined with Bosentan.Approved
AmprenavirThe serum concentration of Amprenavir can be decreased when it is combined with Bosentan.Approved
AntipyrineThe serum concentration of Antipyrine can be decreased when it is combined with Bosentan.Approved
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Bosentan.Approved
ApremilastThe serum concentration of Apremilast can be decreased when it is combined with Bosentan.Approved, Investigational
AprepitantThe serum concentration of Bosentan can be increased when it is combined with Aprepitant.Approved, Investigational
ArgatrobanThe serum concentration of Argatroban can be decreased when it is combined with Bosentan.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Bosentan.Approved, Investigational
ArtemetherThe serum concentration of Artemether can be decreased when it is combined with Bosentan.Approved
AsenapineThe serum concentration of Asenapine can be decreased when it is combined with Bosentan.Approved
AstemizoleThe serum concentration of Astemizole can be decreased when it is combined with Bosentan.Approved, Withdrawn
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Bosentan.Approved, Investigational
AtenololAtenolol may increase the hypotensive activities of Bosentan.Approved
AtomoxetineThe serum concentration of Bosentan can be increased when it is combined with Atomoxetine.Approved
AtorvastatinThe metabolism of Atorvastatin can be increased when combined with Bosentan.Approved
AvanafilThe serum concentration of Avanafil can be decreased when it is combined with Bosentan.Approved
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Bosentan.Approved, Investigational
AzelastineThe serum concentration of Azelastine can be decreased when it is combined with Bosentan.Approved
AzithromycinThe serum concentration of Azithromycin can be decreased when it is combined with Bosentan.Approved
BanoxantroneThe serum concentration of Banoxantrone can be decreased when it is combined with Bosentan.Investigational
BedaquilineThe serum concentration of Bedaquiline can be decreased when it is combined with Bosentan.Approved
BenazeprilBenazepril may increase the hypotensive activities of Bosentan.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Bosentan.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Bosentan.Withdrawn
BenzphetamineThe serum concentration of Benzphetamine can be decreased when it is combined with Bosentan.Approved, Illicit
Benzyl alcoholThe serum concentration of Benzyl alcohol can be decreased when it is combined with Bosentan.Approved
BepridilBosentan may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Bosentan.Approved
BethanidineBethanidine may increase the hypotensive activities of Bosentan.Approved
BexaroteneThe serum concentration of Bexarotene can be decreased when it is combined with Bosentan.Approved, Investigational
BezafibrateThe serum concentration of Bezafibrate can be decreased when it is combined with Bosentan.Approved
BicalutamideThe serum concentration of Bicalutamide can be decreased when it is combined with Bosentan.Approved
BimatoprostBosentan may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololThe serum concentration of Bisoprolol can be decreased when it is combined with Bosentan.Approved
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Bosentan.Approved
BortezomibThe serum concentration of Bosentan can be increased when it is combined with Bortezomib.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Bosentan.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Bosentan.Approved
BretyliumBosentan may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be decreased when it is combined with Bosentan.Approved
BrimonidineBrimonidine may increase the hypotensive activities of Bosentan.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Bosentan.Approved
BrinzolamideThe serum concentration of Brinzolamide can be decreased when it is combined with Bosentan.Approved
BromazepamThe serum concentration of Bromazepam can be decreased when it is combined with Bosentan.Approved, Illicit
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Bosentan.Approved, Investigational
BrompheniramineThe serum concentration of Brompheniramine can be decreased when it is combined with Bosentan.Approved
BudesonideThe serum concentration of Budesonide can be decreased when it is combined with Bosentan.Approved
BupivacaineThe serum concentration of Bupivacaine can be decreased when it is combined with Bosentan.Approved, Investigational
BupranololBosentan may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe serum concentration of Buprenorphine can be decreased when it is combined with Bosentan.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Bupropion can be decreased when it is combined with Bosentan.Approved
BuspironeThe serum concentration of Buspirone can be decreased when it is combined with Bosentan.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be decreased when it is combined with Bosentan.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Bosentan.Approved
CabergolineThe serum concentration of Cabergoline can be decreased when it is combined with Bosentan.Approved
CabozantinibThe serum concentration of Cabozantinib can be decreased when it is combined with Bosentan.Approved
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Bosentan.Approved
CalcitriolThe serum concentration of Calcitriol can be decreased when it is combined with Bosentan.Approved, Nutraceutical
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Bosentan.Approved
CandesartanBosentan may increase the hypotensive activities of Candesartan.Approved
CandoxatrilBosentan may increase the hypotensive activities of Candoxatril.Experimental
CapecitabineThe serum concentration of Bosentan can be increased when it is combined with Capecitabine.Approved, Investigational
CaptoprilBosentan may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe serum concentration of Carbamazepine can be decreased when it is combined with Bosentan.Approved, Investigational
CarbinoxamineThe serum concentration of Carbinoxamine can be decreased when it is combined with Bosentan.Approved
CariprazineThe serum concentration of Cariprazine can be decreased when it is combined with Bosentan.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Bosentan.Withdrawn
CarteololCarteolol may increase the hypotensive activities of Bosentan.Approved
CarvedilolThe serum concentration of Carvedilol can be decreased when it is combined with Bosentan.Approved, Investigational
CelecoxibThe serum concentration of Celecoxib can be decreased when it is combined with Bosentan.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be decreased when it is combined with Bosentan.Approved, Investigational
CephalexinThe serum concentration of Cephalexin can be decreased when it is combined with Bosentan.Approved, Vet Approved
CeritinibThe serum concentration of Bosentan can be increased when it is combined with Ceritinib.Approved
CerivastatinThe metabolism of Cerivastatin can be increased when combined with Bosentan.Withdrawn
CevimelineThe serum concentration of Cevimeline can be decreased when it is combined with Bosentan.Approved
Chenodeoxycholic acidThe serum concentration of Chenodeoxycholic acid can be decreased when it is combined with Bosentan.Approved
ChlordiazepoxideThe serum concentration of Chlordiazepoxide can be decreased when it is combined with Bosentan.Approved, Illicit
ChloroquineThe serum concentration of Chloroquine can be decreased when it is combined with Bosentan.Approved, Vet Approved
ChlorothiazideBosentan may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Bosentan.Withdrawn
ChlorphenamineThe serum concentration of Chlorphenamine can be decreased when it is combined with Bosentan.Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Bosentan.Approved, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Bosentan.Approved
ChlorzoxazoneThe serum concentration of Chlorzoxazone can be decreased when it is combined with Bosentan.Approved
CholecalciferolThe serum concentration of Bosentan can be increased when it is combined with Cholecalciferol.Approved, Nutraceutical
Cholic AcidBosentan may decrease the excretion rate of Cholic Acid which could result in a higher serum level.Approved
CiclesonideThe serum concentration of Ciclesonide can be decreased when it is combined with Bosentan.Approved, Investigational
CilazaprilBosentan may increase the hypotensive activities of Cilazapril.Approved
CilostazolThe serum concentration of Cilostazol can be decreased when it is combined with Bosentan.Approved
CinacalcetThe serum concentration of Cinacalcet can be decreased when it is combined with Bosentan.Approved
CisaprideThe serum concentration of Cisapride can be decreased when it is combined with Bosentan.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Bosentan.Approved
ClarithromycinThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Bosentan.Approved
ClemastineThe serum concentration of Bosentan can be increased when it is combined with Clemastine.Approved
ClindamycinThe serum concentration of Clindamycin can be decreased when it is combined with Bosentan.Approved, Vet Approved
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Bosentan.Approved, Illicit
ClofazimineThe serum concentration of Clofazimine can be decreased when it is combined with Bosentan.Approved, Investigational
ClofibrateThe serum concentration of Clofibrate can be decreased when it is combined with Bosentan.Approved
clomethiazoleThe serum concentration of clomethiazole can be decreased when it is combined with Bosentan.Investigational
ClomipramineThe serum concentration of Clomipramine can be decreased when it is combined with Bosentan.Approved, Vet Approved
ClonazepamThe serum concentration of Clonazepam can be decreased when it is combined with Bosentan.Approved, Illicit
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Bosentan.Approved
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Bosentan.Approved, Nutraceutical
ClorazepateThe serum concentration of Clorazepate can be decreased when it is combined with Bosentan.Approved, Illicit
ClotiazepamThe serum concentration of Clotiazepam can be decreased when it is combined with Bosentan.Approved, Illicit
ClotrimazoleThe serum concentration of Bosentan can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Bosentan.Approved
CobicistatThe serum concentration of Bosentan can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Bosentan.Approved
CocaineThe serum concentration of Cocaine can be decreased when it is combined with Bosentan.Approved, Illicit
CodeineThe serum concentration of Codeine can be decreased when it is combined with Bosentan.Approved, Illicit
Coenzyme Q10The metabolism of Coenzyme Q10 can be increased when combined with Bosentan.Experimental
ColchicineThe serum concentration of Colchicine can be decreased when it is combined with Bosentan.Approved
ConivaptanThe serum concentration of Bosentan can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Bosentan.Approved
Cortisone acetateThe serum concentration of Cortisone acetate can be decreased when it is combined with Bosentan.Approved
CrizotinibThe serum concentration of Bosentan can be increased when it is combined with Crizotinib.Approved
CryptenamineBosentan may increase the hypotensive activities of Cryptenamine.Approved
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Bosentan.Approved
CyclophosphamideThe serum concentration of Cyclophosphamide can be decreased when it is combined with Bosentan.Approved, Investigational
CyclosporineThe serum concentration of Bosentan can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideBosentan may increase the hypotensive activities of Cyclothiazide.Approved
CytarabineThe serum concentration of Cytarabine can be decreased when it is combined with Bosentan.Approved, Investigational
DabrafenibThe serum concentration of Bosentan can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Daclatasvir can be decreased when it is combined with Bosentan.Approved
DantroleneThe serum concentration of Dantrolene can be decreased when it is combined with Bosentan.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Bosentan.Approved
DapsoneThe serum concentration of Dapsone can be decreased when it is combined with Bosentan.Approved, Investigational
DarifenacinThe serum concentration of Darifenacin can be decreased when it is combined with Bosentan.Approved, Investigational
DarunavirThe serum concentration of Darunavir can be decreased when it is combined with Bosentan.Approved
DasabuvirThe serum concentration of Dasabuvir can be decreased when it is combined with Bosentan.Approved
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Bosentan.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Bosentan.Approved
DebrisoquinBosentan may increase the hypotensive activities of Debrisoquin.Approved
DeferasiroxThe serum concentration of Bosentan can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Bosentan can be increased when it is combined with Delavirdine.Approved
DeserpidineBosentan may increase the hypotensive activities of Deserpidine.Approved
DesogestrelThe serum concentration of Desogestrel can be decreased when it is combined with Bosentan.Approved
DesvenlafaxineThe serum concentration of Desvenlafaxine can be decreased when it is combined with Bosentan.Approved
DexamethasoneThe serum concentration of Dexamethasone can be decreased when it is combined with Bosentan.Approved, Investigational, Vet Approved
DextromethorphanThe serum concentration of Dextromethorphan can be decreased when it is combined with Bosentan.Approved
DextropropoxypheneThe serum concentration of Dextropropoxyphene can be decreased when it is combined with Bosentan.Approved, Illicit, Withdrawn
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Bosentan.Approved, Illicit, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Bosentan.Approved
DiclofenacThe serum concentration of Diclofenac can be decreased when it is combined with Bosentan.Approved, Vet Approved
DicoumarolThe metabolism of Dicoumarol can be increased when combined with Bosentan.Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Bosentan.Approved
DienogestThe serum concentration of Dienogest can be decreased when it is combined with Bosentan.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Bosentan.Approved
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Bosentan.Approved
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Bosentan.Approved
DihydralazineBosentan may increase the hypotensive activities of Dihydralazine.Investigational
DihydrocodeineThe serum concentration of Dihydrocodeine can be decreased when it is combined with Bosentan.Approved, Illicit
DihydroergotamineThe serum concentration of Bosentan can be increased when it is combined with Dihydroergotamine.Approved
DiltiazemThe serum concentration of Bosentan can be increased when it is combined with Diltiazem.Approved
DisopyramideThe serum concentration of Disopyramide can be decreased when it is combined with Bosentan.Approved
DisulfiramThe serum concentration of Disulfiram can be decreased when it is combined with Bosentan.Approved
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Bosentan.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be decreased when it is combined with Bosentan.Approved
DolasetronThe serum concentration of Dolasetron can be decreased when it is combined with Bosentan.Approved
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Bosentan.Approved, Investigational, Vet Approved
DonepezilThe serum concentration of Donepezil can be decreased when it is combined with Bosentan.Approved
DorzolamideThe serum concentration of Dorzolamide can be decreased when it is combined with Bosentan.Approved
DoxazosinBosentan may increase the hypotensive activities of Doxazosin.Approved
DoxepinThe serum concentration of Doxepin can be decreased when it is combined with Bosentan.Approved
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Bosentan.Approved, Investigational
DoxycyclineThe serum concentration of Bosentan can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be decreased when it is combined with Bosentan.Approved, Illicit
DronedaroneThe serum concentration of Bosentan can be increased when it is combined with Dronedarone.Approved
DrospirenoneThe serum concentration of Drospirenone can be decreased when it is combined with Bosentan.Approved
DutasterideThe serum concentration of Dutasteride can be decreased when it is combined with Bosentan.Approved, Investigational
EfavirenzThe serum concentration of Bosentan can be increased when it is combined with Efavirenz.Approved, Investigational
EfonidipineBosentan may increase the hypotensive activities of Efonidipine.Approved
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Bosentan.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be decreased when it is combined with Bosentan.Approved
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Bosentan.Approved
EnalaprilThe serum concentration of Enalapril can be decreased when it is combined with Bosentan.Approved, Vet Approved
EnalaprilatBosentan may increase the hypotensive activities of Enalaprilat.Approved
EnzalutamideThe serum concentration of Enzalutamide can be decreased when it is combined with Bosentan.Approved
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Bosentan.Approved, Investigational
EplerenoneThe serum concentration of Eplerenone can be decreased when it is combined with Bosentan.Approved
EpoprostenolBosentan may increase the hypotensive activities of Epoprostenol.Approved
EprosartanBosentan may increase the hypotensive activities of Eprosartan.Approved
ErgocalciferolThe serum concentration of Ergocalciferol can be decreased when it is combined with Bosentan.Approved, Nutraceutical
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Bosentan.Approved
ErgonovineThe serum concentration of Ergonovine can be decreased when it is combined with Bosentan.Approved
ErgotamineThe serum concentration of Ergotamine can be decreased when it is combined with Bosentan.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Bosentan.Approved, Investigational
ErythromycinThe serum concentration of Bosentan can be increased when it is combined with Erythromycin.Approved, Vet Approved
EscitalopramThe serum concentration of Escitalopram can be decreased when it is combined with Bosentan.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Bosentan can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe serum concentration of Esomeprazole can be decreased when it is combined with Bosentan.Approved, Investigational
EstazolamThe serum concentration of Estazolam can be decreased when it is combined with Bosentan.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Bosentan.Approved, Investigational, Vet Approved
Estradiol valerate/DienogestThe serum concentration of Estradiol valerate/Dienogest can be decreased when it is combined with Bosentan.Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Bosentan.Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Bosentan.Approved
EstroneThe serum concentration of Estrone can be decreased when it is combined with Bosentan.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Bosentan.Approved
EszopicloneThe serum concentration of Eszopiclone can be decreased when it is combined with Bosentan.Approved
EthanolThe serum concentration of Ethanol can be decreased when it is combined with Bosentan.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Bosentan.Approved
EthosuximideThe serum concentration of Ethosuximide can be decreased when it is combined with Bosentan.Approved
Ethyl biscoumacetateThe metabolism of Ethyl biscoumacetate can be increased when combined with Bosentan.Withdrawn
EthylmorphineThe serum concentration of Ethylmorphine can be decreased when it is combined with Bosentan.Approved, Illicit
Ethynodiol diacetateThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Bosentan.Approved
EtonogestrelThe serum concentration of Etonogestrel can be decreased when it is combined with Bosentan.Approved, Investigational
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Bosentan.Approved
EtoricoxibThe serum concentration of Etoricoxib can be decreased when it is combined with Bosentan.Approved, Investigational
EtravirineThe serum concentration of Bosentan can be increased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be decreased when it is combined with Bosentan.Approved
ExemestaneThe serum concentration of Exemestane can be decreased when it is combined with Bosentan.Approved, Investigational
FamciclovirThe serum concentration of Famciclovir can be decreased when it is combined with Bosentan.Approved
FelbamateThe serum concentration of Felbamate can be decreased when it is combined with Bosentan.Approved
FelodipineThe serum concentration of Felodipine can be decreased when it is combined with Bosentan.Approved, Investigational
FenofibrateThe serum concentration of Fenofibrate can be decreased when it is combined with Bosentan.Approved
FenoldopamBosentan may increase the hypotensive activities of Fenoldopam.Approved
FentanylThe serum concentration of Fentanyl can be decreased when it is combined with Bosentan.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Bosentan.Approved
FinasterideThe serum concentration of Finasteride can be decreased when it is combined with Bosentan.Approved
FingolimodThe serum concentration of Fingolimod can be decreased when it is combined with Bosentan.Approved, Investigational
FlibanserinThe serum concentration of Flibanserin can be decreased when it is combined with Bosentan.Approved
FloxuridineThe serum concentration of Bosentan can be increased when it is combined with Floxuridine.Approved
FluconazoleThe serum concentration of Bosentan can be increased when it is combined with Fluconazole.Approved
FluindioneThe metabolism of Fluindione can be increased when combined with Bosentan.Investigational
FlunisolideThe serum concentration of Flunisolide can be decreased when it is combined with Bosentan.Approved, Investigational
FlunitrazepamThe serum concentration of Flunitrazepam can be decreased when it is combined with Bosentan.Approved, Illicit
FluorometholoneThe serum concentration of Fluorometholone can be decreased when it is combined with Bosentan.Approved
FluorouracilThe serum concentration of Bosentan can be increased when it is combined with Fluorouracil.Approved
FluoxetineThe serum concentration of Fluoxetine can be decreased when it is combined with Bosentan.Approved, Vet Approved
FlurazepamThe serum concentration of Flurazepam can be decreased when it is combined with Bosentan.Approved, Illicit
FlutamideThe serum concentration of Flutamide can be decreased when it is combined with Bosentan.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Bosentan.Approved
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be decreased when it is combined with Bosentan.Approved
FluvastatinThe metabolism of Fluvastatin can be increased when combined with Bosentan.Approved
FluvoxamineThe serum concentration of Bosentan can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Fosamprenavir can be decreased when it is combined with Bosentan.Approved
FosaprepitantThe serum concentration of Bosentan can be increased when it is combined with Fosaprepitant.Approved
FosinoprilFosinopril may increase the hypotensive activities of Bosentan.Approved
FosphenytoinThe metabolism of Bosentan can be increased when combined with Fosphenytoin.Approved
FulvestrantThe serum concentration of Fulvestrant can be decreased when it is combined with Bosentan.Approved, Investigational
FurazolidoneFurazolidone may increase the hypotensive activities of Bosentan.Approved, Vet Approved
Fusidic AcidThe serum concentration of Bosentan can be increased when it is combined with Fusidic Acid.Approved
GalantamineThe serum concentration of Galantamine can be decreased when it is combined with Bosentan.Approved
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Bosentan.Approved, Investigational
GemfibrozilThe serum concentration of Bosentan can be increased when it is combined with Gemfibrozil.Approved
GestodeneThe serum concentration of Gestodene can be decreased when it is combined with Bosentan.Approved
GlipizideThe serum concentration of Glipizide can be decreased when it is combined with Bosentan.Approved
GlyburideGlyburide may increase the hepatotoxic activities of Bosentan.Approved
GranisetronThe serum concentration of Granisetron can be decreased when it is combined with Bosentan.Approved, Investigational
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Bosentan.Withdrawn
GuanabenzBosentan may increase the hypotensive activities of Guanabenz.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Bosentan.Approved
GuanethidineBosentan may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe serum concentration of Guanfacine can be decreased when it is combined with Bosentan.Approved, Investigational
HalofantrineThe serum concentration of Halofantrine can be decreased when it is combined with Bosentan.Approved
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Bosentan.Approved
HalothaneThe serum concentration of Halothane can be decreased when it is combined with Bosentan.Approved, Vet Approved
HexamethoniumBosentan may increase the hypotensive activities of Hexamethonium.Experimental
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Bosentan.Withdrawn
HexobarbitalThe serum concentration of Hexobarbital can be decreased when it is combined with Bosentan.Approved
Histamine PhosphateThe serum concentration of Histamine Phosphate can be decreased when it is combined with Bosentan.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Bosentan.Approved
HydralazineBosentan may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideBosentan may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Bosentan.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Bosentan.Approved, Vet Approved
HydroflumethiazideBosentan may increase the hypotensive activities of Hydroflumethiazide.Approved
HydromorphoneThe serum concentration of Hydromorphone can be decreased when it is combined with Bosentan.Approved, Illicit
Hydroxyprogesterone caproateThe serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Bosentan.Approved
IbrutinibThe serum concentration of Ibrutinib can be decreased when it is combined with Bosentan.Approved
IdelalisibThe serum concentration of Bosentan can be increased when it is combined with Idelalisib.Approved
IfosfamideThe serum concentration of Ifosfamide can be decreased when it is combined with Bosentan.Approved
IloperidoneThe serum concentration of Iloperidone can be decreased when it is combined with Bosentan.Approved
IloprostIloprost may increase the hypotensive activities of Bosentan.Approved, Investigational
ImatinibThe serum concentration of Bosentan can be increased when it is combined with Imatinib.Approved
ImidaprilBosentan may increase the hypotensive activities of Imidapril.Investigational
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Bosentan.Approved
ImiquimodThe serum concentration of Imiquimod can be decreased when it is combined with Bosentan.Approved, Investigational
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Bosentan.Approved
IndapamideThe serum concentration of Indapamide can be decreased when it is combined with Bosentan.Approved
IndenololBosentan may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Bosentan can be increased when it is combined with Indinavir.Approved
IndoraminBosentan may increase the hypotensive activities of Indoramin.Withdrawn
Ipratropium bromideThe serum concentration of Ipratropium bromide can be decreased when it is combined with Bosentan.Approved
IproclozideIproclozide may increase the hypotensive activities of Bosentan.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Bosentan.Withdrawn
IrbesartanThe serum concentration of Bosentan can be increased when it is combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Bosentan.Approved, Investigational
IsavuconazoniumThe serum concentration of Bosentan can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Bosentan.Approved
Isosorbide DinitrateThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Bosentan.Approved
Isosorbide MononitrateThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Bosentan.Approved
IsradipineThe serum concentration of Bosentan can be increased when it is combined with Isradipine.Approved
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Bosentan.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be decreased when it is combined with Bosentan.Approved
IvacaftorThe serum concentration of Bosentan can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Bosentan.Approved, Vet Approved
IxabepiloneThe serum concentration of Ixabepilone can be decreased when it is combined with Bosentan.Approved, Investigational
IxazomibThe serum concentration of Ixazomib can be decreased when it is combined with Bosentan.Approved
KetamineThe serum concentration of Ketamine can be decreased when it is combined with Bosentan.Approved, Vet Approved
KetanserinBosentan may increase the hypotensive activities of Ketanserin.Investigational
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Bosentan.Approved
KetobemidoneThe serum concentration of Ketobemidone can be decreased when it is combined with Bosentan.Approved
KetoconazoleThe serum concentration of Bosentan can be increased when it is combined with Ketoconazole.Approved, Investigational
LabetalolBosentan may increase the hypotensive activities of Labetalol.Approved
LacidipineBosentan may increase the hypotensive activities of Lacidipine.Approved
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Bosentan.Approved, Investigational
LapatinibThe serum concentration of Lapatinib can be decreased when it is combined with Bosentan.Approved, Investigational
LaquinimodThe serum concentration of Laquinimod can be decreased when it is combined with Bosentan.Investigational
LatanoprostBosentan may increase the hypotensive activities of Latanoprost.Approved, Investigational
LeflunomideThe serum concentration of Bosentan can be increased when it is combined with Leflunomide.Approved, Investigational
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Bosentan.Approved
LercanidipineThe serum concentration of Lercanidipine can be decreased when it is combined with Bosentan.Approved, Investigational
LetrozoleThe serum concentration of Letrozole can be decreased when it is combined with Bosentan.Approved, Investigational
LevobupivacaineThe serum concentration of Levobupivacaine can be decreased when it is combined with Bosentan.Approved
LevocetirizineThe serum concentration of Levocetirizine can be decreased when it is combined with Bosentan.Approved
Levomethadyl AcetateThe serum concentration of Levomethadyl Acetate can be decreased when it is combined with Bosentan.Approved
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Bosentan.Approved
LevonorgestrelThe serum concentration of Levonorgestrel can be decreased when it is combined with Bosentan.Approved, Investigational
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Bosentan.Approved
LidocaineThe serum concentration of Lidocaine can be decreased when it is combined with Bosentan.Approved, Vet Approved
LisinoprilBosentan may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisurideThe serum concentration of Lisuride can be decreased when it is combined with Bosentan.Approved
LofexidineBosentan may increase the hypotensive activities of Lofexidine.Approved, Investigational
LomitapideThe serum concentration of Lomitapide can be decreased when it is combined with Bosentan.Approved
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Bosentan.Approved
LopinavirThe serum concentration of Bosentan can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Loratadine can be decreased when it is combined with Bosentan.Approved
LorcaserinThe serum concentration of Lorcaserin can be decreased when it is combined with Bosentan.Approved
LosartanThe serum concentration of Bosentan can be increased when it is combined with Losartan.Approved
LovastatinThe metabolism of Lovastatin can be increased when combined with Bosentan.Approved, Investigational
LuliconazoleThe serum concentration of Bosentan can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Bosentan can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe serum concentration of Lumefantrine can be decreased when it is combined with Bosentan.Approved
LurasidoneThe serum concentration of Lurasidone can be decreased when it is combined with Bosentan.Approved
LynestrenolThe serum concentration of Lynestrenol can be decreased when it is combined with Bosentan.Investigational
MacitentanThe serum concentration of Macitentan can be decreased when it is combined with Bosentan.Approved
ManidipineBosentan may increase the hypotensive activities of Manidipine.Approved
MaravirocThe serum concentration of Maraviroc can be decreased when it is combined with Bosentan.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Bosentan.Withdrawn
MebendazoleThe serum concentration of Mebendazole can be decreased when it is combined with Bosentan.Approved, Vet Approved
MecamylamineBosentan may increase the hypotensive activities of Mecamylamine.Approved
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Bosentan.Approved, Investigational
MefloquineThe serum concentration of Mefloquine can be decreased when it is combined with Bosentan.Approved
MeloxicamThe serum concentration of Meloxicam can be decreased when it is combined with Bosentan.Approved, Vet Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Bosentan.Approved
MethadoneThe serum concentration of Methadone can be decreased when it is combined with Bosentan.Approved
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Bosentan.Experimental
MethaqualoneThe serum concentration of Methaqualone can be decreased when it is combined with Bosentan.Illicit, Withdrawn
MethoxsalenThe serum concentration of Methoxsalen can be decreased when it is combined with Bosentan.Approved
MethoxyfluraneThe serum concentration of Methoxyflurane can be decreased when it is combined with Bosentan.Approved, Vet Approved
MethyldopaBosentan may increase the hypotensive activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Bosentan.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Bosentan.Approved, Investigational
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Bosentan.Approved, Vet Approved
MethyltestosteroneThe serum concentration of Methyltestosterone can be decreased when it is combined with Bosentan.Approved
MetipranololBosentan may increase the hypotensive activities of Metipranolol.Approved
MetolazoneMetolazone may increase the hypotensive activities of Bosentan.Approved
MetoprololMetoprolol may increase the hypotensive activities of Bosentan.Approved, Investigational
MetronidazoleThe serum concentration of Metronidazole can be decreased when it is combined with Bosentan.Approved
MetyrosineBosentan may increase the hypotensive activities of Metyrosine.Approved
MevastatinThe metabolism of Mevastatin can be increased when combined with Bosentan.Experimental
MexiletineThe serum concentration of Mexiletine can be decreased when it is combined with Bosentan.Approved
MianserinThe serum concentration of Mianserin can be decreased when it is combined with Bosentan.Approved
MibefradilThe serum concentration of Mibefradil can be decreased when it is combined with Bosentan.Withdrawn
MiconazoleThe serum concentration of Miconazole can be decreased when it is combined with Bosentan.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be decreased when it is combined with Bosentan.Approved, Illicit
MifepristoneThe serum concentration of Bosentan can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineMinaprine may increase the hypotensive activities of Bosentan.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Bosentan.Approved
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Bosentan.Approved
MirtazapineThe serum concentration of Mirtazapine can be decreased when it is combined with Bosentan.Approved
MitotaneThe serum concentration of Bosentan can be decreased when it is combined with Mitotane.Approved
MoclobemideMoclobemide may increase the hypotensive activities of Bosentan.Approved
ModafinilThe serum concentration of Modafinil can be decreased when it is combined with Bosentan.Approved, Investigational
MoexiprilBosentan may increase the hypotensive activities of Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Bosentan.Approved
MontelukastThe serum concentration of Montelukast can be decreased when it is combined with Bosentan.Approved
MorphineThe serum concentration of Morphine can be decreased when it is combined with Bosentan.Approved, Investigational
MoxonidineBosentan may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Bosentan.Approved, Investigational
NadololBosentan may increase the hypotensive activities of Nadolol.Approved
NafcillinThe serum concentration of Bosentan can be decreased when it is combined with Nafcillin.Approved
NaftopidilBosentan may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be decreased when it is combined with Bosentan.Approved
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Bosentan.Approved, Vet Approved
NateglinideThe serum concentration of Nateglinide can be decreased when it is combined with Bosentan.Approved, Investigational
NebivololBosentan may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be decreased when it is combined with Bosentan.Approved, Withdrawn
NelfinavirThe serum concentration of Bosentan can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Bosentan can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Bosentan can be increased when it is combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Bosentan.Withdrawn
NicardipineThe serum concentration of Bosentan can be increased when it is combined with Nicardipine.Approved
NicorandilBosentan may increase the hypotensive activities of Nicorandil.Approved
NicotineThe serum concentration of Nicotine can be decreased when it is combined with Bosentan.Approved
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Bosentan.Approved
NiguldipineBosentan may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe serum concentration of Bosentan can be increased when it is combined with Nilotinib.Approved, Investigational
NilvadipineThe serum concentration of Nilvadipine can be decreased when it is combined with Bosentan.Approved
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Bosentan.Approved
NisoldipineThe serum concentration of Nisoldipine can be decreased when it is combined with Bosentan.Approved
NitrazepamThe serum concentration of Nitrazepam can be decreased when it is combined with Bosentan.Approved
NitrendipineThe serum concentration of Nitrendipine can be decreased when it is combined with Bosentan.Approved
NitroprussideNitroprusside may increase the hypotensive activities of Bosentan.Approved
NorelgestrominThe serum concentration of Norelgestromin can be decreased when it is combined with Bosentan.Approved
NorethisteroneThe serum concentration of Norethisterone can be decreased when it is combined with Bosentan.Approved
NorgestimateThe serum concentration of Norgestimate can be decreased when it is combined with Bosentan.Approved
NorgestrelThe serum concentration of Norgestrel can be decreased when it is combined with Bosentan.Approved
NortriptylineThe serum concentration of Nortriptyline can be decreased when it is combined with Bosentan.Approved
ObinutuzumabBosentan may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Bosentan.Withdrawn
OlaparibThe serum concentration of Olaparib can be decreased when it is combined with Bosentan.Approved
OlmesartanOlmesartan may increase the hypotensive activities of Bosentan.Approved, Investigational
OlopatadineThe serum concentration of Olopatadine can be decreased when it is combined with Bosentan.Approved
OmapatrilatBosentan may increase the hypotensive activities of Omapatrilat.Investigational
OmeprazoleThe serum concentration of Bosentan can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe serum concentration of Ondansetron can be decreased when it is combined with Bosentan.Approved
OrphenadrineThe serum concentration of Orphenadrine can be decreased when it is combined with Bosentan.Approved
OsimertinibThe serum concentration of Bosentan can be increased when it is combined with Osimertinib.Approved
OspemifeneThe serum concentration of Ospemifene can be decreased when it is combined with Bosentan.Approved
OxazepamThe serum concentration of Oxazepam can be decreased when it is combined with Bosentan.Approved
OxprenololBosentan may increase the hypotensive activities of Oxprenolol.Approved
OxybutyninThe serum concentration of Oxybutynin can be decreased when it is combined with Bosentan.Approved, Investigational
OxycodoneThe serum concentration of Oxycodone can be decreased when it is combined with Bosentan.Approved, Illicit, Investigational
OxymorphoneThe serum concentration of Oxymorphone can be decreased when it is combined with Bosentan.Approved, Investigational, Vet Approved
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Bosentan.Approved, Vet Approved
PalbociclibThe serum concentration of Palbociclib can be decreased when it is combined with Bosentan.Approved
PalonosetronThe serum concentration of Palonosetron can be decreased when it is combined with Bosentan.Approved, Investigational
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Bosentan.Approved, Investigational
PantoprazoleThe serum concentration of Pantoprazole can be decreased when it is combined with Bosentan.Approved
ParamethadioneThe serum concentration of Paramethadione can be decreased when it is combined with Bosentan.Approved
ParamethasoneThe serum concentration of Paramethasone can be decreased when it is combined with Bosentan.Approved
ParecoxibThe serum concentration of Parecoxib can be decreased when it is combined with Bosentan.Approved
PargylinePargyline may increase the hypotensive activities of Bosentan.Approved
ParicalcitolThe serum concentration of Paricalcitol can be decreased when it is combined with Bosentan.Approved, Investigational
ParitaprevirThe serum concentration of Paritaprevir can be decreased when it is combined with Bosentan.Approved
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Bosentan.Approved
PenbutololBosentan may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentamidineThe serum concentration of Pentamidine can be decreased when it is combined with Bosentan.Approved
PentobarbitalThe metabolism of Bosentan can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumBosentan may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Bosentan.Approved, Investigational
PerampanelThe serum concentration of Perampanel can be decreased when it is combined with Bosentan.Approved
PergolideThe serum concentration of Pergolide can be decreased when it is combined with Bosentan.Approved, Vet Approved, Withdrawn
PerhexilineThe serum concentration of Perhexiline can be decreased when it is combined with Bosentan.Approved
PerindoprilBosentan may increase the hypotensive activities of Perindopril.Approved
PermethrinThe serum concentration of Permethrin can be decreased when it is combined with Bosentan.Approved, Investigational
PerphenazineThe serum concentration of Perphenazine can be decreased when it is combined with Bosentan.Approved
PethidineThe serum concentration of Pethidine can be decreased when it is combined with Bosentan.Approved
PhenacetinThe serum concentration of Phenacetin can be decreased when it is combined with Bosentan.Withdrawn
PhenelzinePhenelzine may increase the hypotensive activities of Bosentan.Approved
PhenindioneThe metabolism of Phenindione can be increased when combined with Bosentan.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Bosentan.Withdrawn
PhenobarbitalThe metabolism of Bosentan can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineThe serum concentration of Phenoxybenzamine can be decreased when it is combined with Bosentan.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Bosentan.Withdrawn
PhenprocoumonThe metabolism of Phenprocoumon can be increased when combined with Bosentan.Approved
PhentolamineBosentan may increase the hypotensive activities of Phentolamine.Approved
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Bosentan.Approved, Vet Approved
PilocarpineThe serum concentration of Pilocarpine can be decreased when it is combined with Bosentan.Approved
PimecrolimusThe serum concentration of Pimecrolimus can be decreased when it is combined with Bosentan.Approved, Investigational
PimozideThe serum concentration of Pimozide can be decreased when it is combined with Bosentan.Approved
PinacidilThe serum concentration of Pinacidil can be decreased when it is combined with Bosentan.Withdrawn
PindololBosentan may increase the hypotensive activities of Pindolol.Approved
PioglitazoneThe serum concentration of Pioglitazone can be decreased when it is combined with Bosentan.Approved, Investigational
PipotiazineThe serum concentration of Pipotiazine can be decreased when it is combined with Bosentan.Approved
PirlindolePirlindole may increase the hypotensive activities of Bosentan.Approved
PitavastatinThe metabolism of Pitavastatin can be increased when combined with Bosentan.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Bosentan.Withdrawn
PodofiloxThe serum concentration of Podofilox can be decreased when it is combined with Bosentan.Approved
PolythiazideBosentan may increase the hypotensive activities of Polythiazide.Approved
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Bosentan.Approved
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Bosentan.Approved
PosaconazoleThe serum concentration of Posaconazole can be decreased when it is combined with Bosentan.Approved, Investigational, Vet Approved
PrasteroneThe serum concentration of Prasterone can be decreased when it is combined with Bosentan.Approved, Nutraceutical
PrasugrelThe serum concentration of Prasugrel can be decreased when it is combined with Bosentan.Approved
PravastatinThe metabolism of Pravastatin can be increased when combined with Bosentan.Approved
PrazepamThe serum concentration of Prazepam can be decreased when it is combined with Bosentan.Approved, Illicit
PraziquantelThe serum concentration of Praziquantel can be decreased when it is combined with Bosentan.Approved, Vet Approved
PrazosinPrazosin may increase the hypotensive activities of Bosentan.Approved
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Bosentan.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Bosentan.Approved, Vet Approved
PrimaquineThe serum concentration of Primaquine can be decreased when it is combined with Bosentan.Approved
PrimidoneThe metabolism of Bosentan can be increased when combined with Primidone.Approved, Vet Approved
ProchlorperazineThe serum concentration of Prochlorperazine can be decreased when it is combined with Bosentan.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be decreased when it is combined with Bosentan.Approved, Vet Approved
ProguanilThe serum concentration of Proguanil can be decreased when it is combined with Bosentan.Approved
PromazineThe serum concentration of Promazine can be decreased when it is combined with Bosentan.Approved, Vet Approved
PropafenoneThe serum concentration of Propafenone can be decreased when it is combined with Bosentan.Approved
PropofolThe serum concentration of Propofol can be decreased when it is combined with Bosentan.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Bosentan.Approved, Investigational
PyrazinamideThe serum concentration of Pyrazinamide can be decreased when it is combined with Bosentan.Approved
PyrimethamineThe serum concentration of Bosentan can be increased when it is combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe serum concentration of Quazepam can be decreased when it is combined with Bosentan.Approved, Illicit
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Bosentan.Approved
QuinacrineThe serum concentration of Quinacrine can be decreased when it is combined with Bosentan.Approved
QuinaprilBosentan may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Bosentan.Approved
QuinineThe serum concentration of Bosentan can be increased when it is combined with Quinine.Approved
RabeprazoleThe serum concentration of Rabeprazole can be decreased when it is combined with Bosentan.Approved, Investigational
RaloxifeneThe serum concentration of Raloxifene can be decreased when it is combined with Bosentan.Approved, Investigational
RamelteonThe serum concentration of Ramelteon can be decreased when it is combined with Bosentan.Approved, Investigational
RamiprilRamipril may increase the hypotensive activities of Bosentan.Approved
RanolazineThe serum concentration of Ranolazine can be decreased when it is combined with Bosentan.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Bosentan.Approved
ReboxetineThe serum concentration of Reboxetine can be decreased when it is combined with Bosentan.Approved, Investigational
RegorafenibThe serum concentration of Regorafenib can be decreased when it is combined with Bosentan.Approved
RemikirenRemikiren may increase the hypotensive activities of Bosentan.Approved
RepaglinideThe serum concentration of Repaglinide can be decreased when it is combined with Bosentan.Approved, Investigational
RescinnamineBosentan may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Bosentan.Approved
RetapamulinThe serum concentration of Retapamulin can be decreased when it is combined with Bosentan.Approved
RifabutinThe serum concentration of Rifabutin can be decreased when it is combined with Bosentan.Approved
RifampicinThe serum concentration of Bosentan can be decreased when it is combined with Rifampicin.Approved
RifapentineThe metabolism of Bosentan can be increased when combined with Rifapentine.Approved
RilmenidineBosentan may increase the hypotensive activities of Rilmenidine.Investigational
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Bosentan.Approved
RimonabantThe serum concentration of Rimonabant can be decreased when it is combined with Bosentan.Approved, Investigational
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Bosentan.Approved
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Bosentan.Approved, Investigational
RitonavirThe serum concentration of Bosentan can be increased when it is combined with Ritonavir.Approved, Investigational
RituximabBosentan may increase the hypotensive activities of Rituximab.Approved
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Bosentan.Approved
RofecoxibThe serum concentration of Rofecoxib can be decreased when it is combined with Bosentan.Investigational, Withdrawn
RolapitantThe serum concentration of Rolapitant can be decreased when it is combined with Bosentan.Approved
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Bosentan.Approved, Investigational
RopiniroleThe serum concentration of Ropinirole can be decreased when it is combined with Bosentan.Approved, Investigational
RopivacaineThe serum concentration of Ropivacaine can be decreased when it is combined with Bosentan.Approved
RosuvastatinThe metabolism of Rosuvastatin can be increased when combined with Bosentan.Approved
RotigotineThe serum concentration of Rotigotine can be decreased when it is combined with Bosentan.Approved
RoxithromycinThe serum concentration of Roxithromycin can be decreased when it is combined with Bosentan.Approved, Withdrawn
RuxolitinibThe serum concentration of Ruxolitinib can be decreased when it is combined with Bosentan.Approved
SafrazineSafrazine may increase the hypotensive activities of Bosentan.Withdrawn
SalmeterolThe serum concentration of Salmeterol can be decreased when it is combined with Bosentan.Approved
SaprisartanBosentan may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe serum concentration of Saquinavir can be decreased when it is combined with Bosentan.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Bosentan.Approved
SecobarbitalThe metabolism of Bosentan can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe serum concentration of Selegiline can be decreased when it is combined with Bosentan.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Bosentan.Approved
SeratrodastThe serum concentration of Seratrodast can be decreased when it is combined with Bosentan.Approved, Investigational
SertindoleThe serum concentration of Sertindole can be decreased when it is combined with Bosentan.Approved, Withdrawn
SertralineThe serum concentration of Sertraline can be decreased when it is combined with Bosentan.Approved
SevofluraneThe serum concentration of Sevoflurane can be decreased when it is combined with Bosentan.Approved, Vet Approved
SibutramineThe serum concentration of Sibutramine can be decreased when it is combined with Bosentan.Approved, Illicit, Investigational, Withdrawn
SildenafilThe serum concentration of Bosentan can be increased when it is combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be decreased when it is combined with Bosentan.Approved
SiltuximabThe serum concentration of Bosentan can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Bosentan.Approved
SimvastatinThe metabolism of Simvastatin can be increased when combined with Bosentan.Approved
SirolimusThe serum concentration of Sirolimus can be decreased when it is combined with Bosentan.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Bosentan.Approved, Investigational
SitaxentanBosentan may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SolifenacinThe serum concentration of Solifenacin can be decreased when it is combined with Bosentan.Approved
SonidegibThe serum concentration of Sonidegib can be decreased when it is combined with Bosentan.Approved, Investigational
SorafenibThe serum concentration of Bosentan can be increased when it is combined with Sorafenib.Approved, Investigational
SpiramycinThe serum concentration of Spiramycin can be decreased when it is combined with Bosentan.Approved
SpiraprilBosentan may increase the hypotensive activities of Spirapril.Approved
St. John's WortThe serum concentration of Bosentan can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Bosentan can be increased when it is combined with Stiripentol.Approved
SufentanilThe serum concentration of Sufentanil can be decreased when it is combined with Bosentan.Approved, Investigational
SulfadiazineThe serum concentration of Bosentan can be increased when it is combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe serum concentration of Bosentan can be increased when it is combined with Sulfamethoxazole.Approved
SulfinpyrazoneThe serum concentration of Sulfinpyrazone can be decreased when it is combined with Bosentan.Approved
SulfisoxazoleThe serum concentration of Bosentan can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
SunitinibThe serum concentration of Sunitinib can be decreased when it is combined with Bosentan.Approved, Investigational
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Bosentan.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Synthetic Conjugated Estrogens, B can be decreased when it is combined with Bosentan.Approved
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Bosentan.Approved, Investigational
TadalafilThe serum concentration of Tadalafil can be decreased when it is combined with Bosentan.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Bosentan.Approved
TamsulosinThe serum concentration of Tamsulosin can be decreased when it is combined with Bosentan.Approved, Investigational
TasosartanThe serum concentration of Tasosartan can be decreased when it is combined with Bosentan.Approved
Taurochenodeoxycholic acidThe serum concentration of Taurochenodeoxycholic acid can be decreased when it is combined with Bosentan.Experimental
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Bosentan.Approved
TelithromycinThe serum concentration of Telithromycin can be decreased when it is combined with Bosentan.Approved
TelmisartanBosentan may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemazepamThe serum concentration of Temazepam can be decreased when it is combined with Bosentan.Approved
TemocaprilBosentan may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Bosentan.Approved
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Bosentan.Approved
TerbinafineThe serum concentration of Terbinafine can be decreased when it is combined with Bosentan.Approved, Investigational, Vet Approved
TerfenadineThe serum concentration of Terfenadine can be decreased when it is combined with Bosentan.Withdrawn
TerlipressinBosentan may increase the hypotensive activities of Terlipressin.Approved, Investigational
TesmilifeneThe serum concentration of Tesmilifene can be decreased when it is combined with Bosentan.Investigational
TestosteroneThe serum concentration of Testosterone can be decreased when it is combined with Bosentan.Approved, Investigational
TetracyclineThe serum concentration of Tetracycline can be decreased when it is combined with Bosentan.Approved, Vet Approved
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Bosentan.Approved
ThiotepaThe serum concentration of Thiotepa can be decreased when it is combined with Bosentan.Approved
TiagabineThe serum concentration of Tiagabine can be decreased when it is combined with Bosentan.Approved
TiboloneBosentan may increase the hypotensive activities of Tibolone.Approved
TicagrelorThe serum concentration of Bosentan can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe serum concentration of Bosentan can be increased when it is combined with Ticlopidine.Approved
TicrynafenBosentan may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the hypotensive activities of Bosentan.Approved
TinidazoleThe serum concentration of Tinidazole can be decreased when it is combined with Bosentan.Approved, Investigational
TiotropiumThe serum concentration of Tiotropium can be decreased when it is combined with Bosentan.Approved
TipranavirThe serum concentration of Tipranavir can be decreased when it is combined with Bosentan.Approved, Investigational
TocilizumabThe serum concentration of Bosentan can be decreased when it is combined with Tocilizumab.Approved
TofacitinibThe serum concentration of Tofacitinib can be decreased when it is combined with Bosentan.Approved, Investigational
TolazolineBosentan may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideThe serum concentration of Bosentan can be increased when it is combined with Tolbutamide.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Bosentan.Approved
TolterodineThe serum concentration of Tolterodine can be decreased when it is combined with Bosentan.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Bosentan.Approved
TorasemideTorasemide may increase the hypotensive activities of Bosentan.Approved
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Bosentan.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be decreased when it is combined with Bosentan.Approved, Investigational
TramadolThe serum concentration of Tramadol can be decreased when it is combined with Bosentan.Approved, Investigational
TrandolaprilTrandolapril may increase the hypotensive activities of Bosentan.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Bosentan.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Bosentan.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Bosentan.Approved
TravoprostTravoprost may increase the hypotensive activities of Bosentan.Approved
TrazodoneThe serum concentration of Trazodone can be decreased when it is combined with Bosentan.Approved, Investigational
TreprostinilTreprostinil may increase the hypotensive activities of Bosentan.Approved, Investigational
TretinoinThe serum concentration of Tretinoin can be decreased when it is combined with Bosentan.Approved, Investigational, Nutraceutical
TriamcinoloneThe serum concentration of Triamcinolone can be decreased when it is combined with Bosentan.Approved, Vet Approved
TriazolamThe serum concentration of Triazolam can be decreased when it is combined with Bosentan.Approved
TrichlormethiazideBosentan may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinBosentan may increase the hypotensive activities of Trimazosin.Experimental
TrimethadioneThe serum concentration of Trimethadione can be decreased when it is combined with Bosentan.Approved
TrimethaphanBosentan may increase the hypotensive activities of Trimethaphan.Approved
TrimethoprimThe serum concentration of Bosentan can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be decreased when it is combined with Bosentan.Approved
TroglitazoneThe serum concentration of Troglitazone can be decreased when it is combined with Bosentan.Withdrawn
TroleandomycinThe serum concentration of Troleandomycin can be decreased when it is combined with Bosentan.Approved
UdenafilThe serum concentration of Udenafil can be decreased when it is combined with Bosentan.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Bosentan.Approved
UnoprostoneBosentan may increase the hypotensive activities of Unoprostone.Approved
ValdecoxibThe serum concentration of Valdecoxib can be decreased when it is combined with Bosentan.Investigational, Withdrawn
Valproic AcidThe serum concentration of Bosentan can be increased when it is combined with Valproic Acid.Approved, Investigational
ValsartanThe serum concentration of Bosentan can be increased when it is combined with Valsartan.Approved, Investigational
VandetanibThe serum concentration of Vandetanib can be decreased when it is combined with Bosentan.Approved
VanoxerineThe serum concentration of Vanoxerine can be decreased when it is combined with Bosentan.Investigational
VardenafilThe serum concentration of Vardenafil can be decreased when it is combined with Bosentan.Approved
VemurafenibThe serum concentration of Vemurafenib can be decreased when it is combined with Bosentan.Approved
VenetoclaxThe serum concentration of Venetoclax can be decreased when it is combined with Bosentan.Approved
VenlafaxineThe serum concentration of Bosentan can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Bosentan can be increased when it is combined with Verapamil.Approved
VicrivirocThe serum concentration of Vicriviroc can be decreased when it is combined with Bosentan.Investigational
VilanterolThe serum concentration of Vilanterol can be decreased when it is combined with Bosentan.Approved
VilazodoneThe serum concentration of Vilazodone can be decreased when it is combined with Bosentan.Approved
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Bosentan.Approved
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Bosentan.Approved, Investigational
VindesineThe serum concentration of Vindesine can be decreased when it is combined with Bosentan.Approved
VinorelbineThe serum concentration of Vinorelbine can be decreased when it is combined with Bosentan.Approved, Investigational
VinpocetineBosentan may increase the hypotensive activities of Vinpocetine.Investigational
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Bosentan.Approved
VoriconazoleThe serum concentration of Bosentan can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineThe serum concentration of Vortioxetine can be decreased when it is combined with Bosentan.Approved
WarfarinThe metabolism of Warfarin can be increased when combined with Bosentan.Approved
XylometazolineBosentan may increase the hypotensive activities of Xylometazoline.Approved
YohimbineThe serum concentration of Yohimbine can be decreased when it is combined with Bosentan.Approved, Vet Approved
ZafirlukastThe serum concentration of Bosentan can be increased when it is combined with Zafirlukast.Approved, Investigational
ZalcitabineThe serum concentration of Zalcitabine can be decreased when it is combined with Bosentan.Approved
ZaleplonThe serum concentration of Zaleplon can be decreased when it is combined with Bosentan.Approved, Illicit, Investigational
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Bosentan.Approved
ZileutonThe serum concentration of Zileuton can be decreased when it is combined with Bosentan.Approved, Investigational, Withdrawn
ZiprasidoneThe serum concentration of Bosentan can be increased when it is combined with Ziprasidone.Approved
ZolpidemThe serum concentration of Zolpidem can be decreased when it is combined with Bosentan.Approved
ZomepiracThe serum concentration of Zomepirac can be decreased when it is combined with Bosentan.Withdrawn
ZonisamideThe serum concentration of Zonisamide can be decreased when it is combined with Bosentan.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be decreased when it is combined with Bosentan.Approved
Food Interactions
  • Take without regard to meals.
References
Synthesis Reference

Maurizio TADDEI, Diletta Naldini, Pietro Allegrini, Gabriele Razzetti, Simone Mantegazza, “Process for the Preparation of Bosentan.” U.S. Patent US20090156811, issued June 18, 2009.

US20090156811
General ReferencesNot Available
External Links
ATC CodesC02KX01
AHFS Codes
  • 24:12.92
PDB EntriesNot Available
FDA labelDownload (424 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9253
Blood Brain Barrier-0.7419
Caco-2 permeable-0.8956
P-glycoprotein substrateNon-substrate0.5738
P-glycoprotein inhibitor INon-inhibitor0.6175
P-glycoprotein inhibitor IINon-inhibitor0.5092
Renal organic cation transporterNon-inhibitor0.9149
CYP450 2C9 substrateNon-substrate0.5926
CYP450 2D6 substrateNon-substrate0.9117
CYP450 3A4 substrateSubstrate0.5132
CYP450 1A2 substrateNon-inhibitor0.7203
CYP450 2C9 inhibitorInhibitor0.518
CYP450 2D6 inhibitorNon-inhibitor0.8755
CYP450 2C19 inhibitorNon-inhibitor0.5219
CYP450 3A4 inhibitorInhibitor0.8407
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.772
Ames testNon AMES toxic0.6147
CarcinogenicityNon-carcinogens0.6515
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.2676 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9679
hERG inhibition (predictor II)Non-inhibitor0.572
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Actelion ltd
Packagers
Dosage forms
FormRouteStrength
TabletOral125.0 mg
Tablet, film coatedOral125 mg
Tablet, film coatedOral62.5 mg
TabletOral125 mg
TabletOral62.5 mg
Tablet, film coatedOral125 mg/1
Tablet, film coatedOral62.5 mg/1
Tablet, for suspensionOral32 mg
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2071193 No1998-08-252012-06-12Canada
US5292740 No1995-11-202015-11-20Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityPoorly soluble in water (1.0 mg/100 ml) and in aqueous solutions at low pH (0.1 mg/100 ml at pH 1.1 and 4.0; 0.2 mg/100 ml at pH 5.0). Solubility increases at higher pH values (43 mg/100 ml at pH 7.5).Not Available
logP3.7Not Available
Caco2 permeability-5.98ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.00904 mg/mLALOGPS
logP4.18ALOGPS
logP4.94ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)5.8ChemAxon
pKa (Strongest Basic)-0.43ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area145.65 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity166.66 m3·mol-1ChemAxon
Polarizability57.89 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as bipyrimidines and oligopyrimidines. These are organic compounds containing two or more pyrimidine rings directly linked to each other. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazines
Sub ClassPyrimidines and pyrimidine derivatives
Direct ParentBipyrimidines and oligopyrimidines
Alternative Parents
Substituents
  • Bipyrimidine
  • Diaryl ether
  • Benzenesulfonamide
  • Phenylpropane
  • Methoxybenzene
  • Phenol ether
  • Anisole
  • Aminopyrimidine
  • Alkyl aryl ether
  • Imidolactam
  • Benzenoid
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Azacycle
  • Ether
  • Hydrocarbon derivative
  • Primary alcohol
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Alcohol
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Peptide hormone binding
Specific Function:
Non-specific receptor for endothelin 1, 2, and 3. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
Gene Name:
EDNRB
Uniprot ID:
P24530
Molecular Weight:
49643.255 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Gardiner SM, Kemp PA, March JE, Bennett T: Effects of bosentan (Ro 47-0203), an ETA-, ETB-receptor antagonist, on regional haemodynamic responses to endothelins in conscious rats. Br J Pharmacol. 1994 Jul;112(3):823-30. [PubMed:7921608 ]
  3. Gupta SK, Saxena A, Singh U, Arya DS: Bosentan, the mixed ETA-ETB endothelin receptor antagonist, attenuated oxidative stress after experimental myocardial ischemia and reperfusion. Mol Cell Biochem. 2005 Jul;275(1-2):67-74. [PubMed:16335785 ]
  4. Marano G, Palazzesi S, Bernucci P, Grigioni M, Formigari R, Ballerini L: ET(A)/ET(B) receptor antagonist bosentan inhibits neointimal development in collared carotid arteries of rabbits. Life Sci. 1998;63(18):PL259-66. [PubMed:9806221 ]
  5. Richard V, Kaeffer N, Hogie M, Tron C, Blanc T, Thuillez C: Role of endogenous endothelin in myocardial and coronary endothelial injury after ischaemia and reperfusion in rats: studies with bosentan, a mixed ETA-ETB antagonist. Br J Pharmacol. 1994 Nov;113(3):869-76. [PubMed:7858879 ]
  6. Said SA, Ammar el SM, Suddek GM: Effect of bosentan (ETA/ETB receptor antagonist) on metabolic changes during stress and diabetes. Pharmacol Res. 2005 Feb;51(2):107-15. [PubMed:15629255 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
Receptor for endothelin-1. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. The rank order of binding affinities for ET-A is: ET1 > ET2 >> ET3.
Gene Name:
EDNRA
Uniprot ID:
P25101
Molecular Weight:
48721.76 Da
References
  1. Albertini M, Lafortuna CL, Ciminaghi B, Mazzola S, Clement MG: Endothelin involvement in respiratory centre activity. Prostaglandins Leukot Essent Fatty Acids. 2001 Sep;65(3):157-63. [PubMed:11728166 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  3. Kiowski W, Sutsch G, Oechslin E, Bertel O: Hemodynamic effects of bosentan in patients with chronic heart failure. Heart Fail Rev. 2001 Dec;6(4):325-34. [PubMed:11447307 ]
  4. Kramp R, Fourmanoir P, Caron N: Endothelin resets renal blood flow autoregulatory efficiency during acute blockade of NO in the rat. Am J Physiol Renal Physiol. 2001 Dec;281(6):F1132-40. [PubMed:11704565 ]
  5. Martin C, Held HD, Uhlig S: Differential effects of the mixed ET(A)/ET(B)-receptor antagonist bosentan on endothelin-induced bronchoconstriction, vasoconstriction and prostacyclin release. Naunyn Schmiedebergs Arch Pharmacol. 2000 Aug;362(2):128-36. [PubMed:10961375 ]
  6. Sihvola RK, Pulkkinen VP, Koskinen PK, Lemstrom KB: Crosstalk of endothelin-1 and platelet-derived growth factor in cardiac allograft arteriosclerosis. J Am Coll Cardiol. 2002 Feb 20;39(4):710-7. [PubMed:11849873 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Dingemanse J, Schaarschmidt D, van Giersbergen PL: Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. Clin Pharmacokinet. 2003;42(3):293-301. [PubMed:12603176 ]
  2. Dingemanse J, van Giersbergen PL: Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet. 2004;43(15):1089-115. [PubMed:15568889 ]
  3. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name:
ABCB11
Uniprot ID:
O95342
Molecular Weight:
146405.83 Da
References
  1. Fattinger K, Funk C, Pantze M, Weber C, Reichen J, Stieger B, Meier PJ: The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther. 2001 Apr;69(4):223-31. [PubMed:11309550 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 03, 2016 02:44